9. Trevi Therapeutics Inc. (NASDAQ:TRVI)
Trevi Therapeutics takes the No. 9 spot because it offers a very specific and medically relevant biotech story, but it still carries the risk profile of a clinical-stage company that needs more late-stage validation before it can rank higher. The company is developing Haduvio, an investigational oral extended-release nalbuphine therapy for chronic cough conditions, including chronic cough in idiopathic pulmonary fibrosis, non-IPF interstitial lung disease, and refractory chronic cough. That focus may sound narrow to casual investors, but it touches a real unmet medical need. Chronic cough is not just an inconvenience for many patients. It can be exhausting, socially limiting, sleep-disrupting, and difficult to treat when standard therapies do not work.
What makes Trevi interesting for biotech investors is that chronic cough is increasingly being viewed through the lens of nerve hypersensitivity. The company explains that Haduvio acts both centrally and peripherally on the cough reflex arc as a kappa agonist and mu antagonist, targeting opioid receptors that may play a role in cough control. In 2025, Trevi announced positive results from its Phase 2b CORAL trial in patients with IPF chronic cough and from its Phase 2a RIVER trial in patients with refractory chronic cough. That gives TRVI a real clinical foundation, not merely a speculative story built on preclinical hope.
Still, Trevi ranks near the bottom because the market opportunity, while meaningful, may not be as immediately explosive as oncology, wet AMD, lupus nephritis, or commercially launched rare disease drugs. In the world of clinical-stage biotech stocks, investors tend to reward companies with massive market potential, late-stage catalysts, or approved products. Trevi has an interesting pipeline and an underappreciated disease focus, but it still needs stronger commercial visibility and broader investor attention to move closer to the top of the ranking.
Click next to see the following stock...
